Jasim Uddin

2018-06-20 13:29
(893 d 11:40 ago)

Posting: # 18929
Views: 1,900

 Bio-equivalence of IR Tablet against ER Tablet [Design Issues]

Dear Sirs

Does anyone know about BE Study design of Immediate Release Formulation against Extended Release Formulation?

We manufacture Potassium Chloride 600 mg IR tablet. But no RLD is available as IR tablet. RLD SLOW-K 600 mg of Novartis is available as ER tablet.

Is it possible to design BE study of our IR formulation of Potassium Chloride 600 mg against SLOW-K 600 mg ER tablet?

Would appreciate kind advice of the experts in this forum.

Kind regards


Edit: Category changed; see also this post #1[Helmut]
Jasim Uddin

2018-06-24 10:28
(889 d 14:41 ago)

@ Jasim Uddin
Posting: # 18955
Views: 1,460

 Bio-equivalence of IR Tablet against ER Tablet

Hi Sir Helmut

Can you please help me out in the following issue?



Edit: Relax; see also this post #9. Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5[Helmut]
 Admin contact
21,220 posts in 4,427 threads, 1,481 registered users;
online 26 (1 registered, 25 guests [including 23 identified bots]).
Forum time: Monday 00:10 CET (Europe/Vienna)

It’s difficult to work in a group
when you are omnipotent.    John de Lancie (as Q)

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz